©The Author(s) 2025.
World J Gastrointest Pathophysiol. Dec 22, 2025; 16(4): 111432
Published online Dec 22, 2025. doi: 10.4291/wjgp.v16.i4.111432
Published online Dec 22, 2025. doi: 10.4291/wjgp.v16.i4.111432
Table 2 Helicobacter pylori vaccines currently in clinical trials - clinicalTrials.gov database
| Vaccine classification | Intervention/treatment | ClinicalTrials.gov ID | Phase | Status | Sponsor |
| Therapeutic vaccines | Biological: CTA control/biological: IMX101 vaccine | NCT03270800 | 1 | Completed | ImevaX |
| Prophylactic vaccines | Biological: H. pylori vacines/biological: Placebo Vaccine | NCT00736476 | 1 | Completed | Novartis Vaccines |
| Biological: H. pylori vaccine/biological: Placebo | NCT02302170 | 3 | Completed | Jiangsu Province Centers for Disease Control and Prevention | |
| Biological: H. pylori vaccine/biological: Placebo | NCT00613665 | 1 | Completed | Novartis Vaccines |
- Citation: Costa JMC, Aguiar CEO, Oliveira MMGL, Cenci Dietrich V, Lima PHM, Freire JPC, Lemos FFB, Queiroz DMM, de Melo FF. Update on the pathogenesis and clinical management of Helicobacter pylori gastric infection and associated diseases. World J Gastrointest Pathophysiol 2025; 16(4): 111432
- URL: https://www.wjgnet.com/2150-5330/full/v16/i4/111432.htm
- DOI: https://dx.doi.org/10.4291/wjgp.v16.i4.111432